3,4-DAA

3,4-DAA is an orally active Anthranilic acid derivative with potent immunosuppressive activities. 3, 4-DAA can alleviate the severity of colitis through inhibiting Th1 cells response, promoting Th2 cytokines expression and inducing CD4+CD25+ T cells expression[1]. 3,4-DAA suppressed expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) release from EOC20 cells induced by IFN-γ and Lipopolysaccharide[2].

Product Specifications

CAS Number

2117759-07-4

UNSPSC

12352005

Target

NO Synthase

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/3-4-daa.html

Solubility

10 mM in DMSO

Smiles

O=C(C1=C(NC(/C=C/C2=CC=C(C(OC)=C2)OC)=O)C(O)=CC=C1)O

Molecular Formula

C18H17NO6

Molecular Weight

343.33

References & Citations

[1]Quan Wen, et al. N- (3', 4'-dimethoxycinnamonyl) anthranilic acid alleviated experimental colitis by inhibiting autoimmune response and inducing CD4+ CD25+ regulatory T cells production. J Gastroenterol Hepatol. 2013 Aug;28 (8) :1330-8.|[2]Michael Platten, et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science. 2005 Nov 4;310 (5749) :850-5.